Research Events

24 May 2019

Organizers: IRB Barcelona
Date: Friday 24 May, 12.00h
Place: Félix Serratosa, Parc Cientific de Barcelona

Plenary Seminar

27 May 2019 - 4 Jun 2019

The Barcelona Institute of Science and Technology (BIST) and its participating centers are pleased to announce the organization of "From Science to Business", a week-long hands-on workshop with 4-day on-site sessions on entrepreneurship in research, delivered in collaboration with ESADE Business School.


From Science to Business will allow participants to:

31 May 2019

Organizers: IRB Barcelona
Date: Friday 31 May, 12.00h
Place: Felix Serratosa Hall, Parc Cientific de Barcelona

Host: Ángel R. Nebreda, PhD - IRB Barcelona


11 Jun 2019

Date: Tuesday, 11 June, 2019
Time: 09:30  – 13:00
Place: Fèlix Serratosa,  Parc Cientific de Barcelona (PCB)

This short workshop will describe many aspects of heterologous expression in E.coli, from choice of construct design through to methods to improve the levels of soluble expression and options for co-expression. In addition, it will also address expression in eukaryotic hosts, including secreted proteins and ECDs, and options for co-expression.

14 Jun 2019

Cristina Fuster – Unit of Aging & Metabolism
Title: “Understanding the transport mechanism of BBB peptide shuttles: THRre and MiniAp-4 as case studies”
Date and Time: Friday, 14th June 2019, 11h.
Room: Aula magna Enric Casassas. Facultat de Química. UB.




14 Jun 2019

Organizers: IRB Barcelona
Date: Friday 14 June, 12.00h
Place: Felix Serratosa Hall, Parc Cientific de Barcelona

Host: Cayetano González, PhD - IRB Barcelona


13 Nov 2019 - 15 Nov 2019

Date: 13-15 November 2019
Place: Van der Valk hotel, Nijmegen (Netherlands)


Early bird registration period:  April 1 – June 30, 2019

Notification of travel grants awardees:  July 31, 2019

Late registration period:  July 1 – September 16, 2019

Notification of abstract selection:  October 2019


Register here:



18 Nov 2019 - 20 Nov 2019

Stimulation of the immune system by blocking immunosuppressive checkpoints has shown spectacular impact in cancer therapy. There is increasing evidence that immunotherapy might elicit similar outcomes in non-oncological settings. This is the case, for example, of neurodegenerative disorders where blockade of immune checkpoints has beneficial effects.  More generally, aging is associated with a progressive unbalance in the composition and activity of the different components of the immune system.